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Background: Cryptococcal meningitis is a deadly fungal infection. This study aimed to characterize the epidemiology of
cerebral cryptococcosis and to define its prognostic factors.
Methods: This cross-sectional study collected clinical information from cryptococcal meningitis patients with confirmed
cerebral cryptococcosis from 2006 to 2012 at the Changhua Christian Healthcare System to access prognostic factors.
Results: Fifty-nine adult cryptococcal meningitis patients were studied. The incidence at Changhua Christian Healthcare
System was approximately 170 episodes per 100,000 patients within the studied period. Forty-one of 59 cryptococcal
meningitis patients developed complications. Overall, 12 of 59 patients died, for a three-month mortality rate of 20.3 %.
Prognostic factors positively associated with the three-month mortality included age (>55 years), patient delay, prolonged
delay by the doctor in administering antifungal agent therapy, duration of intensive care unit stay, chronic lung disease,
cryptococcemia, headache, altered mental status, positive blood cultures, and high cerebrospinal fluid opening pressure
(≥250 mm H2O).
Conclusions: We strongly recommend early administration of an antifungal agent to each suspected cryptococcal
meningitis patient to decrease both the delay by doctors in administering therapy and the mortality risk. Aggressive and
supportive care for severe cryptococcal meningitis patients is critical to decrease overall mortality from this infection.
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Cryptococcus neoformans-Cryptococcus gattii species
complex is the ubiquitous encapsulated yeast that
causes significant infections, ranging from asymptomatic
pulmonary colonization to life-threatening meningo-
encephalitis [1]. Cryptococcosis is a severe opportunistic
fungal infection causing morbidity and mortality and can
manifest as meningitis, pneumonia, or cryptococcemia in
both immunocompetent and immunocompromised hosts
[2–5]. It is estimated that approximately one million cases
and 625,000 deaths occur annually worldwide from crypto-
coccal meningitis (CM) among HIV-infected individuals,* Correspondence: chenchanghuachad@gmail.com
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creativecommons.org/publicdomain/zero/1.0/but only a few studies have estimated the incidence of CM
among non-HIV-infected patients [3, 6]. CM is not uncom-
mon in Taiwan, and 845 new cases were detected using the
National Health Insurance Research Database between
January 2000 and December 2007 [7]. Tseng et al. [4]
reported that patients infected with C. gattii were more
likely to reside in central Taiwan than those infected with
C. neoformans, but there are few geographic evaluations of
CM in central Taiwan.
Outcomes and treatment failure are usually associated
with underlying conditions, a delay in diagnosis or ab-
sence of treatment with a fungicidal drug [8, 9]. How-
ever, prognostic factors have mostly resulted from
reports of clinical trials conducted in earlier treatment
periods and risks [3, 10–13]. Because medical and surgi-
cal advancements may not serve the rapidly growing
high-risk population of patients, more data on theicle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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necessary.
Although many studies have evaluated CM, some lack
confirmed case studies, contain only mycological data,
only focus on HIV or post-transplantation status, or do
not provide incidence estimates [2, 3, 5, 6, 9, 14, 15].
There has been no comprehensive study providing a risk
assessment for CM. Furthermore, the underlying mecha-
nisms of CM are not yet fully understood, and so the
most effective means of prevention remains unknown.
CM infection is fatal without treatment. As a result,
rapid recognition, diagnosis, and treatment are required.
Little is known about CM in the central Taiwan population.
Therefore, this study reports a retrospective cross-sectional
study for patients with confirmed CM at Changhua
Christian Healthcare System (CCHS) between 2006
and 2012 with two specific aims: to characterize the
epidemiology of cerebral cryptococcosis at CCHS and




The population of Changhua, Nantou, and Yunlin coun-
ties is mostly served by the CCHS, which has maintained
comprehensive clinical records since 1867. These three
counties are located in central Taiwan and had a popula-
tion of 1,362,563 in 2014. CCHS is a 3200-bed medical
institute in central Taiwan. Changhua Christian Hospital,
part of the CCHS, is a 1800-bed tertiary referral medical
center located in northern Changhua County and has
been a Joint Commission International–accredited hos-
pital since 2009.
Microbiological evaluation, serological examinations, and
antifungal susceptibility testing of Cryptococcus isolates
Cerebrospinal fluid (CSF) samples were routinely sent
for tests to obtain complete white blood cell counts and
differential counts, glucose and protein concentrations,
and India ink stain and cultures. Urine, pus, lung, asci-
tes, pleural effusion, lymph node, and/or other biopsy
tissues and aspiration specimens were collected and sub-
mitted for culturing when indicated. Serum and CSF
cryptococcal antigen titers were determined using com-
mercial latex agglutination tests (Cryptococcus Antigen
Latex Agglutination Test System, Immuno-Mycologics,
Inc., USA). There was no difference in the culture and
identification systems during the study period.
The blood and CSF specimens were cultured in the
BD BACTEC FX (Becton Dickinson, USA) culture sys-
tem, which is fully automated for microorganism growth
detection. A yeast-like microorganism was detected by
microscopic inspection after gram staining, and the
growth characteristics were observed on agar plates.Further identification was performed using the API-32C
(BioMerieux, France) yeast identification system. All
blood isolates were stored at −80 °C in a Thermo Scien-
tific Forma (Thermo Fisher Scientific, USA) 900 series
955 model.
For drug susceptibility testing, all available stored iso-
lates were thawed, inoculated in Sabouraud dextrose
agar, and incubated at 35 °C for 72 h. The procedures
were done according to the manufacturer’s Sensititre
YeastOne protocol (TREK Diagnostic Systems, UK) [16].
Briefly, yeast colonies from the Sabouraud dextrose agar
plates were placed into test tubes containing 10 μL nor-
mal saline and vortexed; the turbidity of the suspensions
was adjusted to a 0.5 McFarland standard. The suspen-
sions were then placed into the panel wells and incu-
bated in a 35 °C incubator for 72 h. A control well
without an antifungal agent (AFA) was used to ensure
the quality of growth and purity. After incubation, the
control suspension was subcultured onto another
Sabouraud dextrose agar plate to ensure the growth of
10-80 pure colonies for each corresponding candida
isolate. The panel wells were read and interpreted auto-
matically using a Vizion instrument (Thermo Scientific
Sensititre Vizion Digital MIC Viewing System, Thermo
Fisher Scientific, UK).Definitions
CM was defined as a CSF culture positive for C.
neoformans-C. gattii species complex in this study.
Time until diagnosis was defined by the duration of
symptoms (in days), that is, the number of days
between symptom onset and meeting of the case def-
inition. Patient delay was defined as the interval be-
tween the onset of symptoms and initial presentation
to the hospital. Delay by the doctor in administering
AFA therapy was defined as the interval between the
initial presentation to the hospital and the start of
AFA. Prolonged delay was defined as a delay greater
than the median. Delay by the doctor in administering
steroid therapy was defined as the interval between
the initial presentation to the hospital and the start of
steroid therapy. Prolonged delay was defined as a delay
greater than the median. The patients were divided
into two groups: the deceased group (comprising pa-
tients who died within three months of CM diagnosis)
and the survival group (comprising those still living
after three months). The median of prolonged delay of
AFA was six days. In terms of AFA administration, pa-
tients were divided into two groups: the delayed group
was defined as those patients who received AFA more
than six days after admission and the non-delayed
group was defined as those patients who received AFA
within six days of admission.
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Diagnosis of cryptococcosis was defined in this study
according to a review of microbiological reports, The
International Classification of Diseases, 9th revision (ICD-
9). Cases were sorted in computerized indices by ICD-9
diagnosis in codes 117.5 and 321.0. The medical charts of
CCHS employed were from January 1, 2006, to December
31, 2012 [17]. CM was defined as a CSF culture positive
for C. neoformans-C. gattii species complex in this study,
and the definitive diagnosis of CM was established based
on the presence of symptoms and/or signs suggestive of
meningitis, a CSF culture positive for C. neoformans-C.
gattii species complex, and a CSF smear positive for India
ink. Brain computed tomography and/or magnetic reson-
ance imaging studies were performed on admission, at the
discretion of the physician; and follow-up brain images
were dependent on the physician’s decision.
Between January 2006 and December 2012, hospital-
ized patients aged more than 18 years and diagnosed
with CM were recruited. Each patient had a medical
chart, which contained medical diagnoses, surgical inter-
ventions, and other key information from the medical
records. The medical records of all CM cases were
manually reviewed by the primary investigator (CCH) to
confirm the diagnosis using CCHS resources. Cases that
were judged problematic were reviewed by the second-
ary investigator (SSY). Only the first CM episode in each
person during the study period was included for statis-
tical analyses. To calculate disease incidence, the entire
admitted patient population of CCHS was considered at
risk for infection. All Cryptococcus isolates cultured from
CSF were considered clinically significant. CM was
defined as the isolation of Cryptococcus from CSF in
an adult patient (age ≥ 18 years) between January 1,
2006, and December 31, 2012. We excluded those
patients who presented the following conditions: less than
18 years old, polymicrobial bacteremia (C. neoformans-C.
gattii species complex with another pathogen), incomplete
data, or inconsistency between the data from, ICD-9 diag-
nosis codes 117.5 and 321.0 and the microbiological
dataset.
Validity and reliability of methods
A small-scale validity study was performed on the case-
finding procedures. The validity of the system was tested
by a review of the complete medical charts of 59 individ-
uals who did not have any relevant code in ICD-9; re-
cords were obtained from the microbiological dataset on
or before December 31, 2012 (the end of the study
period). To examine the reliability of both the case-
finding procedure and the diagnoses, all cases judged
problematic by the infectious disease specialist (CCH)
were evaluated. Among the 65 cases examined, the panel
accepted 59 diagnoses (91 %) and revised six.Evaluation and investigation
A standardized case report form was used to collect data
on age, sex, site of involvement, underlying disease,
clinical presentation, length of symptoms, diagnostic la-
boratory and radiographic reports, medical treatment, in-
terventions, and outcomes [17]. Severity of stroke was
defined according to the Canadian Neurological Scale
[18]. Concomitant diseases included hypertension, chronic
kidney disease, diabetes, hyperlipidemia, preexisting car-
diovascular disease, and previous stroke. Hypertension,
chronic kidney disease, diabetes, and hyperlipidemia were
defined according to previous recommendations [19–22].
Stroke, heart failure, atrial fibrillation, and congestive
heart failure were identified by taking a history and by
reviewing the medical chart.Treatment and follow-up
AFA was classified according to drugs administered for
induction, consolidation, and chronic suppression [17].
Induction was defined by the initial drug given for more
than three days [17]. Consolidation was defined as the
therapy given following a response to the induction
regimen [17]. Chronic suppression represented the on-
going maintenance of AFA given to patients without
evidence of active disease [17]. The duration of AFA and
the daily dose were recorded; and the primary outcome
was the three-month mortality in this study. Mortality
attributable to cryptococcosis was also analyzed. A
follow-up record was maintained from the date of diag-
nosis to the date of death or to the date of the last avail-
able record. For the statistical analysis, mild to moderate
sequelae and severe sequelae were regarded as poor
brain outcomes.Statistical analysis
Clinical, neuroradiological, and CSF data were compared
between groups. The χ2 or Fisher’s exact test was used
for binary variables, and Student t-test was employed for
age comparisons between the two groups. Because pa-
tient delay, delay by the doctor in administering AFA,
delay by the doctor in administering corticosteroid ther-
apy, and total delay were not normally distributed, the
nonparametric Mann–Whitney test was used to com-
pare delay differences between groups. Multivariable
analyses for prognostic factors related to three-month
mortality were performed using multiple logistic regres-
sion analysis. Odds ratios (ORs) and their corresponding
95 % confidence intervals (95 % CIs) were also estimated
using ordinary logistic regression. After univariate estimates
were calculated, ORs were obtained in multivariate models
for all independent variables. A p value < 0.05 was consid-
ered statistically significant. All data were analyzed using
the software SPSS (version 17).
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Patient characteristics: laboratory and radiographic
findings
Sixty-five CM patients were enrolled during the study
period, but because of incomplete data and inconsistent
diagnosis, only 59 were analyzed. The incidence of CM
in adults consulting CCHS was not increased, ranging
from 168.9/100,000 patient in 2006 to 172.3/100,000 pa-
tient in 2012. There was no significant linear trend for
an annual increase in CM across the study period. Of
the 59 patients analyzed (Table 1), 43 (72.9 %) had dia-
betes mellitus, 12 (20.3 %) were HIV-positive, and 32
(54.2 %) had malignancies. Cryptococcemia was noted in
21 (35.6 %) and pulmonary cryptococcosis in 21 (35.6 %)
patients.
Before admission, 26 (44.1 %) patients exhibited symp-
tomatic headache, 21 (35.6 %) had fever, and 20 (33.9 %)
had altered mental status. Twenty-six (44.1 %) patients
showed a high CSF opening pressure (>180 mm H2O),
and 18 (30.5 %) patients showed a CSF opening pressure
higher than 250 mm H2O. Every patient received AFA.
Thirty-nine (66.1 %) patients received amphotericin
B deoxycholate (deoxy-AmB) or lipid formulation
amphotericin B (lipid-AmB) with flucytosine (5-FC),
14 (23.7 %) patients received deoxy-AmB or lipid-
AmB with fluconazole (FLU), and six (10.2 %) patients
received FLU. Forty-one (69.5 %) CM patients devel-
oped complications, including 41 with respiratory fail-
ure, 29 with hydrocephalus, 19 with hepatitis, and six
with stroke. Eleven (44 %) of the 25 patients with
hydrocephalus underwent an operation. Overall, 12 of
the 59 CM patients died, for an overall mortality rate
of 20.3 %.
Of the 59 CM patients, a cryptococcal antigen (CrAg)
titer from either serum or CSF was elevated in every pa-
tient (Table 1). Fifteen (25.4 %) and 14 (23.7 %) patients
showed elevated titers (>1:512) in serum and CSF, re-
spectively. Median serum CrAg was 1:256 (interquartile
range 1:16–1:2,048) and median CSF CrAg was 1:256
(interquartile range 1:16–1:2,048). The proportion of
patients with positive CSF cultures was similar across
groups, 82-86 % (p = 0.722). All 59 CM patients received
a head computed tomography or brain magnetic res-
onance imaging; 29 (49.2 %) patients demonstrated
hydrocephalus, 6 (10.2 %) had cryptococcoma, 10
(17.0 %) had basal meningeal enhancement, and 14
(23.7 %) were normal.
As we know, this is the first study to evaluate the risk
factors and clinical outcomes of CM patients in central
Taiwan.
Treatment and outcomes
As to induction therapy, 39 (66.1 %) patients received a
combination of either deoxy-AmB or lipid-AmB plus 5-FC. Fourteen (23.7 %) patients received a combination of
deoxy-AmB or lipid-AmB plus FLU. Finally, six (10.2 %)
received FLU alone. Most patients received a 200–
400 mg average daily dose of FLU. Comparison of induc-
tion regimens with combination therapy, as measured by
the three-month mortality, is presented in Table 2.
In this study, 20.3 % of CM patients died within three
months, which is a lower percentage than that in Tseng’s
previous report [5]. The present study is a large, single-
site, cross-sectional series of well-described, confirmed
CM cases in a population that focuses on the prognostic
factors associated with mortality. Factors observed asso-
ciated with mortality included monotherapy, respiratory
failure, cryptococcemia, length of stay in the ICU, base-
line high CSF opening pressure (≥250 mm H2O), patient
delay, prolonged delay by the doctor in administering
AFA, and age (>55 years). On the other hand, mortality
was not related to neuroradiological findings (basal men-
ingeal enhancement, hydrocephalus, and cryptococ-
coma) or CSF CrAg titer, cerebral stoke, or antifungal
susceptibility tests.
Prognostic factors
Table 1 summarizes the important clinical, neuroradio-
logical, and CSF findings in both groups. A three-month
mortality rate was 20.3 % among all patients. Twenty
deaths (60 %) were attributable to cryptococcosis, ac-
cording to available data. In univariate analyses, prog-
nostic factors associated with three-month mortality
included age (>55 years) (p = 0.192), length of stay in the
intensive care unit (ICU; p < 0.001), chronic lung disease
(p = 0.024), cryptococcemia (p = 0.032), headache (p =
0.031), altered mental status (p = 0.005), and high CSF
opening pressure (≥250 mm H2O) (p = 0.032). In
multivariate logistic regression analyses, monotherapy
(OR 16.5, 95 % CI 2.257–120.639, p = 0.006), respiratory
failure (OR 5.217, 95 % CI 1.030–26.425, p = 0.046), crypto-
coccemia (OR 5.09, 95 % CI 2.540–10.220, p < 0.001), ICU
length of stay (OR 4.217, 95 % CI 1.030–23.025, p = 0.034),
baseline high CSF opening pressure (≥250 mm H2O) (OR
2.93, 95 % CI 1.25–6.88, p = 0.013), and age (>55 years)
(OR 1.07, 95 % CI 1.030–1.146, p = 0.019) were associated
with increased odds of mortality.
Table 2 summarizes the risk factors for mortality in
both groups. The median delay by the doctor in admin-
istering AFA therapy for all patients was six days, and
the median delay by the doctor in administering cortico-
steroid therapy among corticosteroid-treated patients
was eight days; these values were set as the cutoff points
to define prolonged delays by the doctors.
There was no difference in the durations of delay by
the doctors in administering AFA therapy (p = 0.484) or
corticosteroids (p = 0.022) between the two groups.
After univariate logistic regression analysis, the OR for
Table 1 Comparison of key variables between the survivor and deceased groups of CM patients
Variables Survivor group Deceased group Total Univariate logistic regression analysis
n = 47 (%) n = 12 (%) n = 59 p value OR 95 % CI p value
Age > 55 years 18 2 20 0.192 1.077 1.013–1.146 0.019
Gender – male 28 (59.6) 10 (83.6) 38 0.182
Prior cryptococcal infection, not related to this episode 11 (23.4) 2 (16.7) 13 0.762
Length of stay in the ICU (days), median (range) 5 (1–21) 8 (1–48) – <0.001 5.217 1.030-26.425 0.046
Underlying disease
DM 34 (72.3) 9 (75.0) 43 0.052
HTN 31 (66.0) 6 (50.0) 37 0.334
Chronic lung disease 20 (42.6) 9 (75.0) 29 0.024 0.34 0.100-1.240 0.09
Hyperlipidemia 26 (55.3) 6 (50.0) 32 0.102
Previous TB infection 2 (4.3) 1 (8.3) 3 0.203
CV disease 26 (55.3) 4 (33.3) 30 1
Renal disease 16 (34.0) 4 (33.3) 20 0.102
Malignancy, other than hematological malignancy 26 (55.3) 6 (50.0) 32 0.102
Hematological malignancy 25 (53.2) 5 (41.7) 30 0.181
Hematological disease 23 (48.9) 5 (41.7) 28 1
Autoimmune disease 23 (48.9) 3 (25.0) 26 0.591
Psychiatric disease 16 (34.0) 5 (41.7) 21 1
HIV 10 (21.3) 2 (16.7) 12 1
Site of infection
Pulmonary cryptococcosis 13 (27.7) 8 (66.7) 21 0.074 0.44 0.180–1.070 0.07
Cryptococcemia 12 (25.5) 9 (75.0) 21 0.032 5.09 2.540–10.220 <0.001
Clinical presentation
Fever 15 (31.9) 6 (50.0) 21 0.315
Malaise 13 (27.7) 2 (16.7) 15 0.381
Weight loss 12 (25.5) 1 (8.3) 13 0.281
Headache 24 (51.1) 2 (16.7) 26 0.031 3.3 0.696-15.642 0.133
Visual change 7 (14.9) 1 (8.3) 8 0.67
Cranial nerve palsy 2 (4.3) 2 (16.7) 4 1
Cough 10 (21.3) 2 (16.7) 12 1
Dyspnea 9 (19.1) 1 (8.3) 10 1
Altered mental status 12 (25.5) 8 (66.7) 20 0.005 4.09 1.540-9.220 <0.001
Abdominal pain 42 (89.4) 8 (66.7) 50 0.083
Decreased urine output 24 (51.1) 4 (33.3) 28 0.109
Diagnostic criteria
Serum CrAg 1:512 13 (27.7) 2 (16.7) 15 0.381
CSF CrAg >1:512 10 (21.3) 4 (33.3) 14 0.281
CSF white cell count (cell/mm3) (mean, SD) 83.4 ± 32.6 80.4 ± 30.6 – 0.849
CSF % lymphocytes (mean, SD) 207.4 ± 109.8 177.4 ± 82.8 – 0.781
CSF protein (mg/dL; mean, SD) 0.25 ± 0.22 0.22 ± 0.20 – 0.35
CSF blood glucose (mean, SD) −94 ± 175.1 −90 ± 155.2 – 0.674
CSF response (day 14 vs. day 1; mean, SD) 83.4 ± 32.6 80.4 ± 30.6 – 0.943
CSF opening pressure > 250 mm H2O 12 (25.5) 6 (50.0) 18 0.032 2.93 1.250-6.880 0.023
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Table 1 Comparison of key variables between the survivor and deceased groups of CM patients (Continued)
Neuroradiological findings
Basal meningeal enhancement 6 (12.8) 4 (33.3) 10 0.059
Hydrocephalus 20 (42.6) 9 (75.0) 29 0.117
Cryptococcoma 4 (8.5) 2 (16.7) 6 0.589
Neurosurgical intervention 5 (10.6) 6 (50.0) 11 0.147
Stroke 4 (8.5) 2 (16.7) 6 0.591
CI: confidence interval; CM: cryptococcal meningitis; CrAg: cryptococcal antigen; CSF: cerebrospinal fluid; CV: cardiovascular; DM: diabetes mellitus; HIV: human
immunodeficiency virus; HTN: hypertension; ICU: intensive care unit; OR: odds ratio; SD: standard deviation; TB: tuberculosis
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0.006), respiratory failure (OR 5.217, 95 % CI 1.030–
26.425, p = 0.046), cryptococcemia (OR 5.09, 95 % CI
2.540–10.220, p < 0.001), length of stay in the ICU (OR
4.217, 95 % CI 1.030–23.025, p = 0.034), baseline high
CSF opening pressure (≥250 mm H2O) (OR 2.93, 95 %
CI 1.250–6.880, p = 0.013), patient delay (OR 1.87, 95 %
CI 1.274–11.230, p = 0.008), prolonged delay by the
doctor in administering AFA (OR 1.45, 95 % CI 1.080–
12.070, p = 0.008), and age (>55 years) (OR 1.07, 95 %
CI 1.030–1.146, p = 0.019) were significantly higher in
the deceased group.
Patients older than 55 years and those presenting with
headache, altered mental status, and high CSF opening
pressure had an increased risk of death. The association
between high intracranial pressure and mortality was ex-
pected because aggressive management of high intracra-
nial pressure is known to be crucial. These results are
consistent with those of published studies [23, 24]. Ty-
pical CM patients presenting with fever, headache, and se-
vere CM disease will also present with an altered mental
status. The results of our multivariate model were con-
sistent with prior studies showing that an altered mental
status increased the OR of death [2, 3, 25].
The present results showed increased risk of death
among patients with cryptococcemia. These data are
similar to that of Liao’s study [23]. The current finding
having a strong association with three-month mortality
was a positive blood fungal culture. The magnitude of
these results at our institution may explain an emergence
of patients with cryptococcemia. In the present data, the
association of cryptococcemia with poorer outcome is per-
haps not surprising because of its correlation with more
severe and/or disseminated disease [3, 26]. The association
between high intracranial pressure and mortality was
expected, as discussed in the previous paragraph.
Patients presenting with headache and altered mental
status, features linked with elevated intracranial pres-
sure, were associated with a high risk of mortality [3].
The results of the multivariate model were consistent
with prior studies showing that altered mental status in-
creased the OR of death [2, 3, 25]. A previous analysis of
52 patients with cryptococcemia diagnosed during 1981and 2001 in Taiwan showed that cirrhosis and severity
of sepsis were associated with 30-day mortality [26].
Nussbaum et al. evaluated 230 patients between 1997
and 2001 reported neurological signs and symptoms, ab-
normal neuroimaging, and hematological malignancy as
predictors of 90-day mortality [27].
The results of our multivariate analyses revealed an as-
sociation between the drugs used for induction and mor-
tality, which is in contrast with the study by Sun et al.
[28], in which patients who received lipid-AmB had re-
duced ORs of death. Studies in varied patient popula-
tions have shown a beneficial role for combination
therapy with 5-FC; differential administration in those
studies may have contributed to the apparent benefit of
lipid-AmB [10, 13, 17]. The current data comparing six
CM patients who received FLU monotherapy revealed a
lower mortality rate than those that received combi-
nation therapy (OR 16.5, 95 % CI 2.257–120.63, p = 0.006;
Table 2). The reason the previously mentioned six pa-
tients received FLU monotherapy was a lack of 5-FC in
Taiwan during the early period of this study; in addition,
it was not appropriate for them to receive deoxy-AmB
because of renal function impairment.
The present analysis provides strengths over previous
studies, but the observational design was limited by con-
founding indications. The results of some comparisons
should be interpreted carefully, such as in the study by
Bicanic et al. [29]. Those patients with non-CNS disease
who received FLU alone had the lowest mortality, seem-
ingly reflecting less severe underlying disease in contrast
to that in therapeutic populations [29]. Clinicians’ per-
ception of patients’ severity of illness and underlying dis-
eases may have resulted in different management.
Although several covariates were measured, there were
others that were not. We treat patients with more com-
plications and comorbidities at Changhua Christian Hos-
pital in central Taiwan, representing a bias.
Another important strength of this study was selecting
three-month mortality as the primary outcome rather
than a mycological endpoint. Left untreated, CM is a
uniformly fatal disease, but even with AFA treatment,
the outcome is influenced by factors associated with the
host, underlying disease, or the fungus [30]. Several
Table 2 Comparison of induction regimens with combination therapy between survival and deceased groups of CM patients
Variables Survivor group Deceased group Total Univariate logistic
regression analysis
n = 47 (%) n = 12 (%) n = 59 p value OR 95 % CI p value
Mean age (years ± SD) 53.5 ± 17.8 69.2 ± 15.6 56.7 ± 18.4
Age > 55 years 32 (68.1) 10 (83.3) 43 0.019 1.07 1.013-1.146 0.019
Gender – male 18 (38.3) 2 (16.7) 20 0.182
Patient delay 28 (59.6) 10 (83.3) 38 0.012 1.87 1.274-11.230 0.015
Patient delay (days), median (range) 10 (1–124) 9 (1–91) 10 (1–124) 0.389
Delay by the doctor in administering AFA 32 (68.1) 4 (33.3) 36 0.235
Delay by the doctor in administering AFA (days),
median (range)
6 (1–180) 4 (1–28) 6 (1–180) 0.485
Prolonged delay by the doctor in administering
AFA therapy (>6 days)
16 (34.0) 7 (58.3) 23 0.009 1.45 1.080-12.070 0.008
Delay by the doctor in administering corticosteroid 18 (38.3) 5 (41.7) 23 0.062
Delay by the doctor in administering corticosteroid (days),
median (range)
8 (1–14) 9 (1–28) 8 (1–28) 0.389
Total delay 32 (68.1) 10 (83.3) 42 0.055
Total delay (days), median (range) 19 (1–180) 17 (1–91) 19 (1–180) 0.459
Prior cryptococcal infection, not related to this episode 11 (23.4) 2 (16.7) 13 0.762
Length of stay in the ICU (days), median (range) 5 (1–21) 8 (1–28) 5 (1–28) <0.001 4.217 1.030-23.025 0.034
Diagnostic criteria
Serum CrAg >1:512 13 (27.7) 2 (16.7) 15 0.381
CSF CrAg >1:512 10 (21.3) 4 (33.3) 14 0.281
Initial CSF WBC count per mm3, median (range) 9 (0–51) 20 (0–250) 106 0.056
CSF opening pressure > 250 mm H2O 12 (25.5) 6 (50.0) 18 0.032 2.93 1.250-6.880 0.013
Minimum inhibitory concentration of amphotericin
B > 0.5 μg/mL
1 (2.1) 0 1 0.559
Minimum inhibitory concentration of FLU >8 μg/mL 1 (2.1) 0 1 0.862
On AFA
Deoxy-AmB or lipid-AmB + 5-FC 33 (70.2) 6 (50.0) 39 0.005 1
Deoxy-AmB or lipid-AmB + FLU 10 (21.3) 4 (33.3) 14 – 3.3 1.696-15.642 0.133
FLU 2 (4.3) 4 (33.3) 6 – 16.5 2.257-120.639 0.006
Complications
Respiratory failure 29 (61.7) 12 (100.0) 41 <0.001 5.217 1.030-26.425 0.046
Hydrocephalus 20 (42.6) 9 (75.0) 29 0.117
Neurosurgical intervention 5 (10.6) 6 (50.0) 11 0.147
Hepatitis 15 (31.9) 4 (33.3) 19 1
Stroke 4 (8.5) 2 6 0.591
5-FC: flucytosine; AFA: antifungal agent; deoxy-AmB: amphotericin B deoxycholate; CI: confidence interval; CM: cryptococcal meningitis; CrAg: cryptococcal antigen;
CSF: cerebrospinal fluid; FLU: fluconazole; ICU: intensive care unit; lipid-AmB: lipid formulation amphotericin B; OR: odds ratio; SD: standard deviation
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high cerebrospinal fungal burden (demonstrated by high
cryptococcal antigen titers or colony-forming units), dis-
seminated infection, symptomatic elevated intracranial
pressure, low CSF leukocyte cell counts, lack of 5-FC
treatment during induction phase, and induction treat-
ment with low-dose FLU are factors associated with poor
outcome of acquired immune deficiency syndrome-relatedCM [9, 12, 13, 26, 30–35]. Anecdotal reports have indicated
benefit from using corticosteroids in severe cases of para-
doxical cryptococcal immune reconstitution inflammatory
syndrome; but steroids alone in the setting of persistent in-
fection or relapse with FLU-resistant Cryptococcus can
cause harm [36, 37]. There was no significant difference in
the initial prescription of corticosteroid therapy between
the two groups in our study. The decision to initiate
Table 3 Comparison of clinical features, laboratory findings, and outcomes between delayed and non-delayed groups of CM patients
Variables Non-delayed group Delayed group Total Univariate logistic regression analysis
n = 36 (%) n = 23 (%) n = 59 p value OR 95 % CI p value
Mean age (years ± SD) 51.5 ± 16.8 70.2 ± 15.6 56.7 ± 18.4
Age > 55 years 14 (38.3) 6 (26.1) 20 0.182
Gender – male 20 (55.6) 18 (78.3) 38 0.192
Prior cryptococcal infection,
not related to this episode
8 (23.4) 5 (21.7) 13 1.000
Length of stay in the ICU (days),
median (range)
5 (1–21) 7 (1–48) 33 0.275
Underlying disease
DM 26 (71.5) 17 (75.0) 43 0.062
HTN 26 (70.8) 12 (50.0) 37 0.234
Chronic lung disease 12 (32.6) 17 (75.0) 29 0.134
Hyperlipidemia 22 (61.1) 10 (43.5) 32 0.123
Previous TB infection 2 (5.6) 1 (4.3) 3 0.103
CV disease 17 (47.2) 13 (56.5) 30 1.000
Renal disease 11 (30.6) 9 (39.1) 20 0.202
Malignancy, other than hematological
malignancy
11 (30.1) 19 (83.3) 30 0.112
Hematological malignancy 9 (24.5) 19 (83.3) 28 0.181
Hematological disease 5 (13.7) 21 (91.7) 26 1.000
Autoimmune disease 2 (5.1) 19 (83.3) 21 0.059
Psychiatric disease 12 (33.3) 9 (39.1) 21 1.000
HIV 8 (22.7) 4 (16.7) 12 1.000
Site of infection
Pulmonary cryptococcosis 11 (30.6) 10 (43.5) 21 0.084
Cryptococcemia 11 (30.6) 10 (43.5) 21 0.132
Clinical presentation
Fever 11 (31.9) 10 (43.5) 21 0.215
Malaise 10 5 (21.7) 15 0.371
Weight loss 10 (27.7) 5 (21.7) 15 0.181
Headache 18 (51.1) 8 (34.8) 26 0.021 0.23 0.696-15.642 0.023
Visual change 5 (14.9) 3 (13.0) 8 0.670
Cranial nerve palsy 2 (4.3) 2 (8.7) 4 1.000
Cough 8 (21.3) 4 (17.4) 12 1.000
Dyspnea 7 (19.1) 3 (13.0) 10 1.000
Altered mental status 11 (30.6) 9 (39.1) 20 0.011 1.311 1.516-5.642 0.0133
Abdominal pain 35 (97.2) 15 (65.2) 50 0.093
Decreased urine output 13 (36.1) 15 (65.2) 28 0.209
Diagnostic factors
Serum CrAg 1:512 10 (27.7) 5 (21.7) 15 0.381
CSF CrAg >1:512 9 (25.0) 5 (21.7) 14 0.281
CSF opening pressure > 250 mm H2O 10 (27.8) 8 (34.8) 18 0.185
Neuroradiological findings
Basal meningeal enhancement 4 (11.1) 6 (26.1) 10 0.059
Hydrocephalus 19 (52.8) 10 (43.5) 29 0.117
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Table 3 Comparison of clinical features, laboratory findings, and outcomes between delayed and non-delayed groups of CM patients
(Continued)
Cryptococcoma 2 (5.6) 4 (17.4) 6 1.000
Neurosurgical intervention 4 (10.6) 7 (30.4) 11 0.147
Mortality 11 (30.6) 10 (43.5) 23 0.009 1.45 1.080-2.070 0.008
CI: confidence interval; CM: cryptococcal meningitis; CrAg: cryptococcal antigen; CSF: cerebrospinal fluid; CV: cardiovascular; DM: diabetes mellitus; HIV: human
immunodeficiency virus; HTN: hypertension; ICU: intensive care unit; OR: odds ratio; SD: standard deviation; TB: tuberculosis
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going CNS mass effect with surrounding edema.
Most patients who eventually died were admitted to
the ICU because of respiratory insufficiency [38]. The
association between ICU length of stay and occurrence
of respiratory failure, which are known to be crucial, and
mortality was expected [3]. Our results were consistent
with Knaus’s report [38]. According to the original data-
base, hospital mortality of patients with an acute physi-
ology and chronic health evaluation II score of 15 was as
high as 21 % [38, 39]. However, we did not calculate the
ICU length of stay in conjunction with the acute physi-
ology and chronic health evaluation II score in this
study, so we were unable to analyze this in detail.
Delayed group analysis
Table 3 summarizes the clinical features and laboratory
findings and outcomes in the delayed group and the
non-delayed group. The median delay by the doctor in
administering AFA therapy for all patients was six days;
this value was set as the cutoff point to define prolonged
delay by the doctor in administering AFA therapy. As a
result, the delayed group was defined as those patients
who received AFA more than six days after admission.
There was a significant difference in the overall death
rate (p = 0.09) between the two groups. Headache and al-
tered mental status also differed statistically between the
two groups. After univariate logistic regression analysis,
the OR for mortality (OR = 1.45, 95 % CI 1.080-2.070,
p = 0.008), altered mental status (OR = 1.311, 95 % CI
1.516-5.642, p = 0.013), and headache (OR 0.23, 95 % CI
0.696-15.642, p = 0.023) were significantly different be-
tween the two groups.
The present study showed an association among pa-
tient delay (OR = 1.87, 95 % CI 1.274-11.230, p = 0.015)
and delay by the doctor in administering AFA (OR =
1.45, 95 % CI 1.080-2.070, p = 0.008) and the three-
month mortality risk. Although there was a wide range
of intervals between patient presentation and the initi-
ation of AFA because of the nonspecific and highly
variable presentations of CM, we strongly recommend,
firstly, educating the populace to visit a doctor early
when they have a fever and headache and, secondly, that
early empirical AFA be considered when persistent fever
or deteriorated consciousness occurs during the initial
stages of empirical antibacterial therapy.The current study has several strengths. Most impor-
tant was the quality and nearly complete evaluation of
risk assessment variables for patients with confirmed
CM using the dataset from CCHS. Previously reported
CM geographic and demographic data presented variable
results. The validated data of the present study showed
the risk assessment for three-month mortality in patients
with CM. The second strength of the present study is
that it included patients with a diversity of disease sever-
ity (Tables 1 and 2). Third, CCHS provides both primary
care and referred care in central Taiwan; hence, this
study may be representative of CM patients in other
Taiwanese locations. Fourth, we found an association be-
tween delay by the doctor in administering AFA therapy
and the three-month mortality, although a causal rela-
tionship could not be established in this retrospective
study. Fifth, our study involved the use of three-month
mortality as the primary outcome rather than a surro-
gate mycological endpoint that may not be able to dir-
ectly correlate to benefit or harm of clinical patients’
conditions. Last, our study provided the incidence data
for CM during the study period; in adults consulting
CCHS in 2012, the incidence of CM was 172.3/100,000
patient.
However, there are also some important limitations to
this study, partly because of its retrospective nature.
First, the causal relationship between AFA treatment
and CM could not be precisely established. Second, we
did not perform advanced molecular mycological studies
for further evaluation. Kaocharoen et al. [40] showed a
greater genetic diversity and a wider range of major mo-
lecular types between geographic areas. Further evalu-
ation is needed for the molecular analysis. Last, we
served patients with more complications and comorbidi-
ties at Changhua Christian Hospital in central Taiwan,
representing a bias. Our data also reflected the biases of
treatment choices at Changhua Christian Hospital, but
limiting the study initially to a single center increased
internal validity.
Conclusions
Deceased CM patients were found to be older than
those who survived, and death was associated with
monotherapy, respiratory failure, cryptococcemia, length
of stay in the ICU, baseline high CSF opening pressure
(≥250 mm H2O), patient delay, prolonged delay by the
Chen et al. Journal of Venomous Animals and Toxins including Tropical Diseases  (2015) 21:12 Page 10 of 11doctor in administering AFA, and age (>55 years). We
strongly recommend early administration of AFA for
each suspected CM patient as a means of decreasing
both the delay by the doctor in beginning therapy and
the risk of mortality. Controlling the high CSF pressure
can also help alleviate CM’s morbidity and mortality.
Furthermore, aggressive and supportive care for severe CM
patients is critical to decreasing CM’s overall mortality.
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